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Background/Aims: Data are lacking regarding the man-
agement of chronic hepatitis B (CHB) with resistance to 
clevudine (CLV). This study evaluated the efficacy of different 
rescue therapies for CLV-resistant CHB. Methods: Patients 
with CLV-resistant CHB were enrolled in the cohort, and all 
patients developed virologic breakthrough during CLV thera-
py and had confirmed-genotypic resistance to CLV (rtM204I 
mutation) before enrollment. Results: Of the 107 patients, 
12 received adefovir (ADV), 21 received a CLV plus ADV com-
bination (CLV+ADV), 34 received a lamivudine plus ADV com-
bination (LAM+ADV), and 40 received entecavir (ETV) therapy 
for 48 weeks. The CLV+ADV group had the lowest hepatitis B 
virus (HBV) DNA level (p<0.0001) and showed the greatest 
reduction of HBV DNA levels from baseline compared to all 
other groups (p=0.004) at week 48. HBV DNA was undetect-
able (<70 IU/mL) in 0%, 57.1%, 21.2%, and 27.5% (p=0.003) 
of the patients in each group, respectively, at week 48. At the 
end of the study, the mean alanine transaminase (ALT) level, 
rate of ALT normalization, and rate of hepatitis B envelope 
antigen loss or seroconversion did not differ between groups. 
Conclusions: CLV+ADV combination therapy in patients 
with CLV-resistant CHB more effectively suppresses HBV 
replication than ETV, ADV, or LAM+ADV therapy. (Gut Liver 
2017;11:129-135)
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INTRODUCTION
Clevudine (CLV) is a potent antiviral drug approved for 
chronic hepatitis B (CHB) treatment in several Asian countries. 
The initial efficacy of CLV has been demonstrated in 12-week 
and 24-week clinical studies,1-4 and the antiviral effect persists 
even after the drug is stopped, which indicates the drug’s unique 
advantage in terms of relative low viral rebound.1,3 A 48-week 
clinical trial of CLV therapy revealed a potent antiviral effect, 
evidenced by hepatitis B virus (HBV) DNA clearance rates of 
76.6% for the hepatitis B e antigen (HBeAg) positive group, and 
96.3% for the HBeAg negative group; alanine transaminase 
(ALT) normalization rates were 85% and 81% in these respec-
tive groups.5,6 However, CLV-resistance can develop with long-
term treatment. Previous studies have reported CLV-resistance 
in 2% to 14% of patients with no history of lamivudine (LAM) 
exposure, and in about 40% of patients with a history of LAM 
treatment, after 1 year of CLV therapy.5-7 
Although CLV has been used in Korea for several years, data 
are still lacking regarding proper management of CHB with 
resistance to this drug. In CLV-resistant CHB patients, several 
experts and guidelines recommend using the same strategies as 
for resistance to LAM although this suggestion is not based on 
sufficient clinical evidence.8-10 Systematically collected clinical 
data are necessary to support such guidelines.
Various rescue therapies have been used for CLV-resistant 
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CHB patients in Korea before tenofovir (TDF) became avail-
able. These include adefovir (ADV) monotherapy, CLV+ADV 
combination therapy, LAM+ADV combination therapy, and 
entecavir (ETV) monotherapy. Even in the era of TDF, one of 
these regimens may need to be administered in patients who 
are intolerable to TDF. The aim of this multicenter study was 
to compare the efficacy of these rescue therapies in response to 
CLV-resistance. 
MATERIALS AND METHODS
1. Patients 
This cohort study was conducted in 12 hospitals in South 
Korea between May 2008 and November 2011. Eligible patients 
were identified according to the following inclusion criteria: age 
over 18 years, HBeAg positive or negative CHB, more than 6 
months of CLV therapy, development of virologic breakthrough 
during CLV therapy with confirmed genotypic resistance to CLV 
(rtM204I mutation), and rescue therapy for CLV-resistance for 
more than 12 weeks with either ADV, CLV+ADV, LAM+ADV, 
or ETV. The rescue therapy in each case was decided prior to the 
study through discussions between patient and medical doctor. 
Hence, randomization was not performed.
Exclusion criteria were as follows: coinfection with hepatitis 
C virus, hepatitis D virus, or human immunodeficiency virus; 
clinical signs of alcoholism (i.e., weekly consumption over 140 g) 
or drug addiction; current treatment for malignant tumors; and 
current medication with drugs considered to have a direct ef-
fect on viral replication or the liver enzyme levels (e.g., steroids, 
immunosuppressive agents, or nonsteroidal anti-inflammatory 
agents). After enrollment of the cohort, the patients were pro-
spectively followed-up over 48 weeks.
The study was approved by the Institutional Review Boards 
of each institution, and informed written consent was obtained 
from all study participants or their legal guardian, including for 
data sharing. The protocol conforms to the ethical guidelines of 
the Declaration of Helsinki.
2. Study endpoints 
The following variable were evaluated at various time points 
throughout the study: (1) total bilirubin, albumin, aspartate 
transaminase, ALT, HBV DNA (quantitative real-time poly-
merase chain reaction), HBeAg, and anti-HBe (antibody to 
HBeAg), at baseline, 12, 24, 36, and 48 weeks; (2) complete 
blood count, prothrombin time (PT) (international normalized 
ratio, INR), blood urea nitrogen, creatinine, Na, K, Cl, and P, at 
baseline, 24, and 48 weeks; (3) α-fetoprotein, abdominal sonog-
raphy, hepatitis B surface antigen (HBsAg), and anti-HBs (anti-
body to HBsAg) at baseline and 48 weeks; and (4) monitoring of 
adverse events to medication at each outpatient clinic visit. 
The primary study endpoint was proportion of patients with 
undetectable HBV DNA (<70 IU/mL) at 48 weeks, which is de-
fined as a virologic response. Secondary endpoints included un-
detectable HBV DNA at 12, 24, and 36 weeks; normalization of 
Table 1. Comparison of Baseline Characteristics between the Treatment Groups
Parameter
Treatment group
ADV  CLV+ADV LAM+ADV  ETV p-value
Patient 12 21 34 40
Age, yr 48.9±16.2 45.7±8.1 48.1±12.7 44.4±10.4 0.468
Sex (M:F) 3:9 16:5 22:12 29:11 0.014*
HBV DNA, log10 copies/mL 6.19±0.79 5.78±1.18 5.47±1.65 5.85±1.11 0.372
HBeAg 10 18 31 31 0.757
ALT, IU/L 161.9±283.4  151.6±331.0  99.0±116.3 74.7±92.8 0.358
AST, IU/L 87.3±71.3  100.9±191.4 101.2±137.1  65.8±65.7 0.598
Bilirubin, mg/dL 0.71±0.24  0.96±0.28 0.83±0.45  0.89±0.34 0.286
Albumin, g/dL 4.68±0.10  4.41±0.21  4.27±0.40  4.39±0.26 0.001*
Creatinine, mg/dL 0.79±0.21  0.88±0.18  0.86±0.23  0.91±0.22 0.491
PT, INR 0.93±0.08  0.98±0.08  1.03±0.06  1.09±0.17 0.013*
Hemoglobin, g/dL 14.2±1.3  14.7±1.6  15.1±1.7  15.2±0.9 0.306
Platelet, 103/μL 208.0±94.4 230.4±51.5  189.3±48.4  179.0±52.0 0.047*
AFP, ng/mL  3.5±4.7  2.0±1.0  4.8±4.1  5.2±10.5 0.502
Duration of CLV therapy, mo 18.2±5.6 17.2±4.5  20.0±6.5  17.1±5.9 0.374
Data are presented as number or mean±SD. 
ADV, adefovir; CLV, clevudine; LAM, lamivudine; ETV, entecavir; M, male; F, female; HBV DNA, hepatitis B virus DNA; HBeAg, hepatitis B anti-
gen; ALT, alanine transaminase; AST, aspartate transaminase; PT, prothrombin time; INR, international normalized ratio; AFP, α-fetoprotein.
*Significant findings with p<0.05.
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ALT, HBeAg loss, HBeAg seroconversion, and virologic or bio-
chemical breakthroughs at 12, 24, 36, and 48 weeks. The defi-
nitions of virologic breakthrough, biochemical breakthrough, 
primary nonresponse, and partial virologic response followed 
the European Association for the Study of the Liver (EASL) 
guidelines.11
3. Statistical analysis 
Patients who switched therapies or who were lost to follow-
up within 24 weeks were excluded from the final analysis. Com-
parisons of categorical variables were performed with the chi-
square test or the Fischer exact test, while analysis of variance 
(ANOVA) was used to compare continuous variables. A p-value 
<0.05 was considered statistically significant. Statistical analysis 
was performed with SPSS version 12 (SPSS Inc., Chicago, IL, 
USA) by a biomedical statistician (J.M.L.).
RESULTS
1. Study population characteristics 
A total of 118 patients were enrolled in the study. Eleven pa-
tients were excluded from final analysis: two cases had switched 
therapies within 48 weeks (one had elevated creatine phospho-
kinase (CPK) and the other developed symptomatic myopathy), 
and nine cases were lost to follow-up within 24 weeks. The data 
from the remaining 107 patients were analyzed. Patients re-
ceived either ADV (n=12), CLV+ADV (n=21), LAM+ADV (n=34), 
or ETV (n=40) therapy for 48 weeks. Baseline characteristics of 
all patients are shown in Table 1; these did not differ between 
groups, with the exception of sex, serum albumin, PT (INR), 
and platelet counts (p=0.014, p=0.001, p=0.013, and p=0.047, 
respectively). These values were within the normal range in all 
groups, albeit the ETV group had the lowest platelet counts and 
the highest PT (INR), and the LAM+ADV group had the lowest 
albumin levels (Table 1). The HBV DNA level was highest in the 
ADV group compared to all other groups, but this did not reach 
statistical significance (p=0.372) (Table 1). 
2. Virologic and biochemical responses
The CLV+ADV group showed the greatest reduction in HBV 
DNA levels compared to all other groups (p=0.004) (Fig. 1), 
and this group had the lowest HBV DNA level of all groups 
(p<0.0001) (Table 2) at week 48. Mean ALT levels at weeks 12, 
24, 36, and 48 did not differ between groups (Table 3, Fig. 2); 
this was also the case for the proportion of patients achiev-
ing ALT normalization at week 48 (Table 4). However, the 
CLV+ADV group displayed the highest proportion of patients 
with undetectable HBV DNA at week 48 compared to all other 
groups (p=0.002) (Table 4). The proportion of patients achieving 
HBeAg loss or seroconversion at week 48 did not differ between 
groups (Table 4). 
3.	Primary	nonresponse,	partial	virologic	response,	and	 
virologic and biochemical breakthrough 
Primary nonresponse and partial virologic response during 
rescue therapy in patients with CLV-resistance were highest in 
the ADV group and lowest in the CLV+ADV group. The propor-
Fig. 1. Serial changes in hepatitis B virus (HBV) DNA values in pa-
tients with clevudine-resistant chronic hepatitis B. Rescue therapy 
groups: ADV, adefovir; CLV, clevudine; LAM, lamivudine; ETV, ente-
cavir.
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Table 2. Mean HBV DNA Levels according to Time Points in the Four Different Treatment Groups (log10 copies/mL)
Treatment group
Time, wk
p-value
0 12 24 36 48
ADV 6.19±0.79 4.54±0.85 4.63±0.76 3.19±1.25 4.55±0.84 <0.001*
CLV+ADV 5.78±1.18 2.60±1.16 2.57±1.34 2.48±1.22 1.94±0.88 <0.001*
LAM+ADV 5.47±1.65 3.44±1.26 3.20±1.43 3.21±1.51 3.35±1.43 <0.001*
ETV 5.85±1.11 3.42±1.57 3.28±1.37 3.57±1.51 2.97±1.44 <0.001*
p-value 0.372 0.003* 0.002* 0.026* <0.0001*
Data are presented as mean±SD. 
ADV, adefovir; CLV, clevudine; LAM, lamivudine; ETV, entecavir.
*The following comparisons were statistically significant within each column, with p<0.05: CLV+ADV vs LAM+ADV and CLV+ADV vs ETV. Sig-
nificant findings within each column or row.
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tions of patients achieving primary nonresponse in each group 
were as follows: ADV (3/12, 25.0%); CLV+ADV (0/21, 0%); 
LAM+ADV (2/34, 5.9%); and ETV (1/40, 2.5%). Partial virologic 
responses were: ADV group (8/12, 66.6%), CLV+ADV group 
(6/21, 28.6%), LAM+ADV group (16/34, 47.1%), and ETV group 
(18/40, 45.0%). 
At 48 weeks, the proportion of patients with virologic break-
through tended to be lower in the CLV+ADV group, but differ-
ences between groups did not reach statistical significance (Table 
4). In case of virologic breakthrough, therapies were switched 
to ETV+ADV combination in most of cases. Biochemical break-
through rate did not differ between groups; one patient in the 
ADV group, two in the CLV+ADV group, one in the LAM+ADV 
group, and three in the ETV group showed an increase in ALT 
values above upper limit of normal. 
4. Adverse events
Elevation of CPK (>1,000 IU/mL) was observed in three pa-
tients: two from CLV+ADV and one from LAM+ADV group. 
Only one patient in CLV group developed muscle weakness. 
Increase of serum creatinine (>1.5 mg/dL) was noted in one 
patient in CLV+ADV group. Hepatocellular carcinoma was diag-
nosed in one patient in LAM+ADV group during study period.
5. Predictive factors associated with virologic response during 
48 weeks of rescue therapy for clevudine-resistant patients 
The univariate analysis showed that rescue therapy regimen 
(CLV+ADV vs other drugs) and undetectable HBV DNA at 12- 
and 24-week were predictive factors of undetectable HBV DNA 
at 48 weeks (Table 5). The multivariate analysis based on these 
data showed that therapeutic drugs (CLV+ADV) and undetect-
able HBV DNA at 12 weeks were predictive factors related to the 
48-week virologic response (Table 6). When delaying the time 
for prediction of virologic response till 24 weeks, undetectable 
HBV DNA at 24 weeks was the sole factor (Table 6).
Fig. 2. Serial changes in alanine transaminase (ALT) values in pa-
tients with clevudine-resistant chronic hepatitis B. Rescue therapy 
groups: ADV, adefovir; CLV, clevudine; LAM, lamivudine; ETV, ente-
cavir.
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Table 3. Mean ALT Levels according to Time Points in the Four Different Treatment Groups (IU/L)
Treatment group
Time, wk
p-value
0 12 24 36 48
ADV 161.9±283.4 31.4±9.3 28.5±8.8 28.3±8.5 23.7±9.3 <0.001*
CLV+ADV 151.6±331.0 43.8±30.4 31.2±17.7 34.4±28.6  31.9±20.9 <0.001*
LAM+ADV 99.0±116.3 52.5±44.6 38.3±26.4 37.0±33.9 25.2±9.7 <0.001*
ETV 74.7±92.8 44.9±64.5 25.6±13.4  27.8±22.6  37.5±26.6 <0.001*
p-value 0.358 0.698 0.060 0.562 0.074
Data are presented as the mean±SD.
ALT, alanine aminotransferase; ADV, adefovir; CLV, clevudine; LAM, lamivudine; ETV, entecavir.
*Significant differences within each row.
Table 4. Proportion of Patients according to Treatment Responses in the Four Different Groups at Week 48
ADV ADV+CLV ADV+LMV ETV p-value
HBV DNA <70 IU/mL  0/12 (0) 12/21 (57.1)  7/34 (21.2) 11/40 (27.5) 0.002*
ALT normalization 11/12 (91.7) 17/21 (81.0) 29/34 (85.3) 31/40 (77.5) 0.662
HBeAg loss or seroconversion  2/10 (20.0)  2/18 (11.1)  3/31 (9.7)  3/31 (9.7) 0.838
Virologic breakthrough  4/12 (33.3)  4/21 (19.0) 13/34 (38.2) 18/40 (45.0) 0.250
Data are presented as number/total number (%).
ADV, adefovir; CLV, clevudine; LAM, lamivudine; ETV, entecavir; n, number of patients with each response/number of patients who started the 
corresponding rescue therapy; HBV, hepatitis B virus; ALT, alanine transaminase; HBeAg, hepatitis B e antigen.
*Significant differences with p<0.05.
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DISCUSSION
Currently, CLV is not commonly used for initial antiviral 
treatment of CHB patients for several reasons including rela-
tively high incidence of antiviral resistance.5-7 Nevertheless, 
CLV is being prescribed in Korea and in Philippines albeit the 
frequency is decreasing. So far, patients with CLV resistance 
have been treated with various regimens, but no report has been 
published regarding management of CLV resistance. 
This study compared the antiviral effect of rescue therapies in 
CLV-resistant patients divided into four groups according to the 
regimens: ADV, CLV+ADV, LAM+ADV, and ETV. No differences 
were observed in the biochemical response rates among the 
groups, but significant differences were found in the virologi-
cal response rates. The CLV+ADV group displayed the highest 
virologic response whereas the ADV group displayed the lowest 
virologic response. The LAM+ADV group had similar virologic 
response rate to the ETV group. As there are no reports on res-
cue therapy for CLV-resistance, the current recommendation is 
to use the same method as for treatment of LAM-resistance.9,12 
However, according to our data, the LAM+ADV combination 
therapy, which is considered a preferred therapy for LAM-
resistant CHB patients because it induces less drug resistance 
and high viral response, did not show a higher viral suppres-
sive effect than the monotherapies considering the mean HBV 
DNA levels. In terms of virologic response rates, LAM+ADV 
combination therapy for 1 year showed undetectable HBV DNA 
rates of 40% to 70% in previous studies for LAM-resistant 
CHB patients.13,14 However, in our study, this group showed 
low virologic response (21.2% of patients with undetectable 
HBV DNA), whilst 57.1% patients in the CLV+ADV combina-
tion therapy group showed undetectable HBV DNA. In addi-
tion, the LAM+ADV group showed similar rates of virologic 
response rate compared to the monotherapy groups (p=0.121, 
data not shown). It is thought that LAM+ADV combination is 
not very effective for suppressing CLV-resistant HBV. Therefore, 
the LAM+ADV combination should not be considered the first 
recommendation as a rescue therapy for CLV-resistant CHB pa-
tients. 
Table 5. Univariate Analysis of Baseline and On-Treatment Factors 
Related to the Virologic Response in Patients with Clevudine-Resis-
tant Chronic Hepatitis B
OR 95% CI
Drug
    ADV - -
    CLV+ADV  5.600  1.220–25.750
    LAM+ADV  0.660  0.200–2.170
    ETV  1 -
Sex
    Male 2.400  0.820–6.990
    Female  1
HBeAg
    Positive 0.580  0.120–2.830
    Negative  1 -
CLV treatment duration 1.020  0.920–1.130
Age  1  0.960–1.041
AST 1.002  1–1.008
ALT 1.003  1–1.006
Total bilirubin 2.392  0.692–8.270
Albumin 0.651  0.149–2.836
Log HBV DNA 1.039  0.704–1.535
Cr 2.255  0.205–24.828
Platelets 0.999  0.989–1.009
AFP 1.032  0.962–1.107
Sono
    No LC 1.650  0.457–5.964
    LC  1 -
HBV DNA at week 12*, IU/mL
    <70 6.462  1.869–22.345
    >70  1 -
HBV DNA at week 24*, IU/mL
    <70 6.333  1.955–20.517
    >70  1 -
OR, odds ratio; CI, confidence interval; ADV, adefovir; CLV, clevu-
dine; LAM, lamivudine; ETV, entecavir; HBeAg, hepatitis B e anti-
gen; AST, aspartate transaminase; ALT, alanine transaminase; HBV, 
hepatitis B virus; Cr, creatinine; AFP, α-fetoprotein; Sono, abdominal 
ultrasonography; LC, liver cirrhosis.
*All parameters are baseline factors except HBV DNA at week 12 and 
24.
Table 6. Multivariate Analysis of Baseline and On-Treatment Fac-
tors Related to the Virologic Response in Patients with Clevudine-
Resistant Chronic Hepatitis B
 
Model I  Model II
OR 95% CI OR 95% CI
Drug
    ADV - - - -
    CLV+ADV 8.029  1.349–47.775 3.814  0.712–20.433
    LAM+ADV 0.966 0.227–4.109 0.522 0.131–2.074
    ETV 1 - 1 -
HBV DNA at week 12*, IU/mL
    <70 5.253 1.145–24.105
    >70 1 -
HBV DNA at week 24*, IU/mL
    <70   4.307 1.121–16.550
    >70 1 -
OR, odds ratio; CI, confidence interval; ADV, adefovir; CLV, clevu-
dine; LAM, lamivudine; ETV, entecavir; HBV, hepatitis B virus.
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In relation to the treatment effect of the other rescue thera-
pies investigated in this study, ETV monotherapy showed 
similar rates of undetectable HBV DNA and ALT normalization 
to those reported in previous studies in LAM-resistant patients 
with CHB.15-17 However, the mean HBV DNA levels were higher 
than CLV+ADV combination therapy during treatment. The 
ADV monotherapy showed lower antiviral effect than in previ-
ous studies.15,18,19 In particular, none of the ADV group patients 
showed a virologic response at the 48 weeks of treatment. In 
the ADV group, 25% of patients showed a primary nonresponse 
and 66.6% showed a partial virologic response and, therefore, 
91.6% of patients did not achieve virologic response. Only one 
case showed a virologic response (<70 IU/mL) after 36 weeks of 
treatment but experienced virologic breakthrough at 48 weeks 
with a substantial increase in viral load (3240 IU/mL). These 
findings demonstrate that ADV monotherapy is not the proper 
option for the treatment of CLV-resistant CHB. 
In this study, only CLV+ADV combination therapy showed 
an acceptable virologic response rate of 57.1%. The reduction in 
HBV DNA in the CLV+ADV group was significantly greater than 
in all other groups and virologic response rate was significantly 
higher after treatment for 48 weeks. In addition, we evaluated 
the predictive factors for 48 week-virologic response, and it was 
found that CLV+ADV therapy and undetectable HBV DNA at 
12 weeks were the most significant factors. However, two pa-
tients developed increase of CPK, and one of them experienced 
muscle weakness. Muscle-related problems have been reported 
in CHB patients receiving CLV previously.20-23 Incidence of the 
myopathy related to CLV varied 2.9% to 14.6%, and it became 
a major drawback of CLV in clinical use.20-23 Especially, long 
term administration of CLV could be the one of the risk factor 
for its development.21,23 This prevents us from recommending 
CLV+ADV combination for CLV-resistant CHB routinely. In 
addition, ADV has potential risk of nephrotoxicity, and one 
patient of our cohort displayed increase of serum creatinine.14,24 
Hence CLV+ADV combination therapy can only be recommend 
with caution of these adverse events.
Currently, TDF has been approved for patients with chronic 
HBV infection, and known to be more efficacious than ADV.25 
TDF was tested for CHB resistant to LAM,26 ADV,27-29 or ETV,30 
and patients with multiple treatment failures,28,29,31 and TDF 
monotherapy was as effective as combination therapy in these 
population.26,28,30 As TDF is expected superior to LAM+ADV 
combination in LAM-resistant CHB,32 there is high possibility 
of favorable response in CLV-resistant CHB, probably even bet-
ter than CLV+ADV. Unfortunately, we did not have chance to 
evaluate the efficacy of TDF in patients with CLV resistance as 
TDF was not available during the study period in Korea. As TDF 
is still not available in several Asian countries, our data will 
provide important information for choosing rescue therapies in 
CLV resistant CHB. 
This is the first report on the effect of rescue therapies for 
CLV-resistant CHB patients. However, this study had several 
limitations: (1) it was a nonrandomized study as patients were 
recruited in the cohort after starting the rescue therapies; (2) it 
did not include TDF-based therapies; (3) the sample size in each 
rescue therapy group was relatively small; and (4) genotypic re-
sistance was not confirmed in patients with viral breakthrough 
during 48 weeks of the rescue therapies. Therefore, further re-
search with a larger sample size and covering the issues raised 
above is necessary to determine the best option for CLV-resis-
tant CHB patients. 
In conclusion, rescue therapies for CLV-resistant CHB patients 
(ADV, CLV+ADV, LAM+ADV, and ETV) showed similar bio-
chemical response, HBeAg seroconversion rate, and virologic 
breakthrough rate. CLV+ADV combination therapy showed 
an improved virologic response. Several options which have 
used for rescue therapy of LAM-resistant CHB patients (ADV, 
LAM+ADV, and ETV) were not effective in inhibiting viral rep-
lication in CLV-resistant CHB patients.
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